Development of an RSV vaccine for the elderly

Ended Project Grant Awarded Last action

Award ID
R01AI143896
Recipient
Awarding agency
Obligated
$7,885,131

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date
Originally
Funding
  • $7,163,158.92 Federal
  • $721,972.00 Non-federal
Place of performance
Massachusetts, USA

Award details come from USAspending.gov.

Transactions

Action Federal Non-federal Date
Amendment -$1,240 $0
Amendment $72,196 $0
Amendment $649,776 $0
Amendment $649,776 $0
Amendment $721,972 $0
Amendment $721,972 $0
Amendment $721,972 $0
Amendment $721,972 $0
Amendment $721,972 $0
Amendment $721,972 $0
Amendment Development of an RSV vaccine for the elderly - the long-term goal of this project is to develop respiratory syncytial virus (RSV) vaccine candidates for… $721,972 $721,972
Original award $738,847 $0
Show all 12

Subawards

Subrecipient Amount Awarded
Sigmovir Biosystems, Inc. Dr. Blanco’s part of this project will be to perform all animal experiment using the cotton rat model. Dr. Blanco laboratory will assess immune responses… $336,593

Quick answers

Who received award R01AI143896?

R01AI143896 was awarded to University Of Massachusetts Medical School by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on March 2, 2020.

How much is award R01AI143896 worth?

$7,885,131 has been obligated on R01AI143896: $7,163,159 in federal funding and $721,972 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award